COMMUNIQUÉS West-GlobeNewswire

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
13/03/2026
Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access the Akari CEO Corner here TAMPA, Fla. and LONDON, March 13, [...]
SBC Medical to Announce Q4 and Full‑Year 2025 Financial Results
13/03/2026
IRVINE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise [...]
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
13/03/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber [...]
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
13/03/2026
Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the [...]
Sienna Announces March Dividend
13/03/2026
MARKHAM, Ontario, March 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
13/03/2026
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” [...]
SPRINT® PNS System Now Covered Nationally by Aetna®
13/03/2026
- SPRINT PNS is now recognized as a covered treatment option when medically necessary for certain patients with intractable neuropathic pain - CLEVELAND, March 13, 2026 (GLOBE NEWSWIRE) -- SPR ® , a leading private [...]
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
13/03/2026
Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified Islets are [...]
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
13/03/2026
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a [...]
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
13/03/2026
SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Equillium Announces $35 Million Financing with RA Capital Management
13/03/2026
Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, [...]
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
13/03/2026
New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNA Reinforces data [...]
Blue Cross and Blue Shield of Minnesota Advances Collaborative Efforts to Improve Outcomes and Close Gaps in Care
13/03/2026
Excellence in Quality and Outcomes (EQO) Program establishes a shared-data, partnership-driven approach to improving health outcomes EAGAN, Minn., March 13, 2026 (GLOBE NEWSWIRE) -- Blue Cross and Blue Shield of [...]
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
13/03/2026
Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1 Firefly’s AI-powered EEG/ERP technology may [...]
Picard Medical / SynCardia Highlight Total Artificial Heart on BTV Program Airing on FOX Business News
13/03/2026
Segment showcases SynCardia Total Artificial Heart supporting patients with advanced heart failure and next-generation development programs TUCSON, Ariz., March 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE [...]
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
13/03/2026
MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN) 1 , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian [...]
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
13/03/2026
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 [...]
MEDVi and Male Health: What Current Treatment Options Offer
13/03/2026
New York, NY, March 13, 2026 (GLOBE NEWSWIRE) -- Male health is an important aspect of overall wellness, yet many men overlook early symptoms related to energy levels, hormone balance, and sexual performance. Factors [...]
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
13/03/2026
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson’s disease NLRP3 [...]

Pages